Huiliao Bio Participated in the 2024 Vaccine Innovation Forum (VIF) with the Latest Achievements of Veterinary mRNA Vaccines

In the vibrant month of March in Shanghai, the city is alive with the sights and sounds of spring, as the grass grows lush and birds sing joyfully.

At the invitation of the organizing committee of the 2024 Vaccine Innovation Forum World (VIF), Dr. Chen Zhong, Vice President of HuiLiao Bio, delivered a presentation titled "R&D and Industrialization of HuiLiao Bio's mRNA 2.0." Dr. Chen shared the latest advancements in HuiLiao Bio's three major technology platforms—the high-throughput intelligent mRNA design and synthesis platform, the nucleic acid delivery carrier CLS platform, and the Genmax nucleic acid drug production platform—as well as the latest research findings on veterinary mRNA vaccines in target animals (DOI: 10.1128/mbio.02958-23). 

The presentation garnered significant interest and widespread attention from both domestic and international peers, offering valuable insights into the development of domestic mRNA vaccines in the post-pandemic era.

The 2024 Vaccine Innovation Forum, supported by the Shanghai Center for Biopharmaceutical Technology, brought together global leaders in the vaccine industry. Attendees included Professor Shan Lu, former President of the International Society for Vaccines; Dr. Michel De Wilde, Senior Vice President of Vaccines at Sanofi; Dr. Heinrich Haas, Senior Vice President of BioNTech; Professor Petro Terblanche, President of Afrigen Biologics in South Africa; as well as business leaders, academic experts, and representatives from the upstream and downstream vaccine supply chain. Together, they explored the latest advancements in innovative vaccine development and addressed critical issues such as vaccine accessibility and equity worldwide in the post-pandemic era.

#About HuiLiao Bio#

HuiLiao Bio is a high-tech Biotech company specializing in the research and industrialization of nucleic acid drugs. The company's operations span mRNA drug R&D and regulatory submissions, clinical trial design, data analysis, and industrialization. Leveraging its proprietary next-generation mRNA delivery system—the cell-like membrane platform—HuiLiao Bio is developing efficient vaccines for infectious diseases, cancer vaccines, cell therapies, and protein replacement therapies.

Currently, the company has established a comprehensive "trinity" nucleic acid drug R&D and production platform, including the innovative nucleic acid delivery carrier CLS (Cell-Like System) development platform, the Genmax nucleic acid drug production platform, and a high-throughput, intelligent mRNA design and synthesis platform. HuiLiao Bio is committed to advancing the development of next-generation vaccines and therapeutic drugs.